Q1 2024 13F Holders as of 3/31/2024
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
30.3M
-
Number of holders
-
3
-
Total 13F shares, excl. options
-
1.58M
-
Shares change
-
-711K
-
Total reported value, excl. options
-
$5.12M
-
Value change
-
-$15M
-
Number of buys
-
1
-
Number of sells
-
-16
-
Price
-
$3.25
Significant Holders of AN2 Therapeutics, Inc. - Common Stock (ANTX) as of Q1 2024
18 filings reported holding ANTX - AN2 Therapeutics, Inc. - Common Stock as of Q1 2024.
AN2 Therapeutics, Inc. - Common Stock (ANTX) has 3 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 1.58M shares
of 30.3M outstanding shares and own 5.23% of the company stock.
Largest 10 shareholders include CITADEL ADVISORS LLC (1.56M shares), Chicago Partners Investment Group LLC (22K shares), MORGAN STANLEY (4.16K shares), Balyasny Asset Management L.P. (0 shares), FMR LLC (0 shares), Point72 Asia (Singapore) Pte. Ltd. (0 shares), VICTORY CAPITAL MANAGEMENT INC (0 shares), ExodusPoint Capital Management, LP (0 shares), TD Asset Management Inc (0 shares), and Monashee Investment Management LLC (0 shares).
This table shows the top 3 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.